Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

I-Mab and Roche Collaborate on US Trials for Dual Immunotherapy Regimen

publication date: Apr 11, 2019

I-Mab Pharma of Shanghai will collaborate with Roche to conduct US clinical trials that combine I-Mab's TJD5 candidate with Roche's approved anti-PD-L1 treatment, Tecentriq®. I-Mab's TJD5 is a proprietary CD73 antibody that is expected to make checkpoint inhibitors more effective. CD73 is an ecto-enzyme expressed on stromal cells and tumors. It converts extracellular adenosine monophosphate (AMP) to adenosine, which contributes to make the tumor micro-environment more immunosuppressive. In January, I-Mab was granted approval to conduct clinical trials of TJD5 in the US. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020